Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.73 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 4/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.58 |
| ▸ | F2 | P00734 | 1/20 | 0.58 |
| ▸ | F10 | P00742 | 1/20 | 0.58 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.58 |
| ▸ | FEN1 | P39748 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | GCK | P35557 | 1/20 | 0.56 |
| ▸ | PGR | P06401 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL257694 | 0.89 | MMP13 (0.71) | HDAC8AKR1C3NPC1SMN1; SMN2HPGD | |
| SCHEMBL30147470 | 0.87 | GCK (0.59) | HDAC8AKR1C3NPC1SMN1; SMN2HPGD | |
| SCHEMBL9005661 | 0.87 | AKR1C3 (0.68) | HDAC8AKR1C3NPC1PKMSMN1; SMN2 | |
| SCHEMBL177761 | 0.87 | HDAC8 (0.57) | HDAC8AKR1C3NPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL30147517 | 0.85 | NPC1 (0.60) | HDAC8AKR1C3NPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL6671653 | 0.84 | HDAC8 (1.00) | HDAC8AKR1C3NPC1PKMSMN1; SMN2 | |
| SCHEMBL6252549 | 0.84 | HPGD (0.85) | SMN1; SMN2HPGDTSHRHTTERCC5 | |
| SCHEMBL15315479 | 0.84 | HPSE (0.56) | HDAC8AKR1C3SMN1; SMN2HPGDTSHR | |
| SCHEMBL8248607 | 0.83 | ALDH1A1 (0.72) | HDAC8AKR1C3NPC1PKMSMN1; SMN2 | |
| SCHEMBL24074782 | 0.83 | HDAC8 (0.51) | HDAC8AKR1C3NPC1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1301527-A2 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | CORVAS INTERNATIONAL, INC. (US) | 2003-04-16 | — | — | EP | claimed |
| US-20020068702-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | DENDREON PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | claimed |
| WO-2002008251-A2 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | CORVAS INTERNATIONAL, INC. (US) | 2002-01-31 | — | — | WO | claimed |
| WO-2024086767-A2 | GLYCAN CONJUGATE COMPOSITIONS AND METHODS | GANNA BIO, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20230295136-A1 | Analogs of Nitrofuran Antibiotics to Combat Resistance | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2023-09-21 | — | — | US | disclosed |
| CN-115551864-A | Substituted tricyclic amides, analogs thereof, and methods of using the same | 爱彼特生物制药公司 | 2022-12-30 | — | — | CN | disclosed |
| EP-3508484-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-04-07 | — | — | EP | disclosed |
| WO-2020227168-A1 | INHIBITING TRABID | INTEGRAL EARLY DISCOVERY, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2019154306-A1 | SACCHARIDE DERIVATIVES FOR IMMUNE CELL SURFACE MODIFICATION AND USE THEREOF | 厦门诺康得生物科技有限公司 | 2019-08-15 | — | — | WO | disclosed |
| EP-3184514-A1 | AUTOPHAGY INHIBITORS | Deutsches Krebsforschungszentrum (DE) | 2017-06-28 | — | — | EP | disclosed |
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | GAUDINO JOHN | 2011-03-03 | — | — | US | disclosed |
| US-7504431-B2 | Sulfonyl amide inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-17 | — | — | US | disclosed |
| WO-2009033084-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2007103308-A2 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20050245535-A1 | Sulfonyl amide inhibitors of calcium channel function | BRISTOL- MYERS SQUIBB COMPANY | 2005-11-03 | — | — | US | disclosed |
| EP-1301527-A2 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | CORVAS INTERNATIONAL, INC. (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20020068702-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | DENDREON PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | disclosed |
| WO-2002008251-A2 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | CORVAS INTERNATIONAL, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245535-A1 | Sulfonyl amide inhibitors of calcium channel function | CACNA1F, CACNA1A, CACNA1D | HDAC8 1463/4885AKR1C3 2084/4885NPC1 941/4885 |
| US-20020068702-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | VIP, TMPRSS15, TMPRSS11D | HDAC8 3934/4885AKR1C3 2189/4885NPC1 1789/4885 |
| US-20230295136-A1 | Analogs of Nitrofuran Antibiotics to Combat Resistance | ATF4, ATF1, FBL | HDAC8 589/4885AKR1C3 3736/4885NPC1 1389/4885 |
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | TK1, ABL1, ROR1 | HDAC8 3228/4885AKR1C3 731/4885NPC1 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.